Red Blood Cells Protein Profile Is Modified in Breast Cancer Patients (original) (raw)

The purpose of this study was to evaluate whether tumour response to primary chemotherapy in human breast cancer is influenced by baseline haemoglobin (Hb) status. A total of 157 patients with T2-4, N0-1 M0 breast cancer were treated with chemotherapy consisting of either the CMF regimen + tamoxifen (the first 76 cases) or the single-agent epirubicin (the subsequent 81) before definitive surgery. In total, 144 patients were fully assessable. Ki67, p53, bcl-2, c-erbB2, steroid hormone receptor, and microvessel density were evaluated immunohistochemically in tumour specimens obtained before chemotherapy and at surgery. Tumour shrinkage >50% occurred in 72.1% of patients. Responding patients had higher baseline Hb levels and red blood cell counts than nonresponders (P<0.01 and <0.003, respectively). The distribution of disease response according to increasing cutoffs of baseline Hb status showed that from 12.5 mg l(-1) onwards, patients with Hb levels above the cutoff obtained...

Reviews on circulating biomarkers in breast cancer usually focus on one single biomarker or a selective group of biomarkers. An overview summarizing the discovery and evaluation of all blood-based biomarkers in metastatic breast cancer is lacking. This systematic review aims to identify the available evidence of known blood-based biomarkers in metastatic breast cancer, regarding their clinical utility and state-of-the-art position in the validation process. The initial search yielded 1078 original studies, of which 420 were assessed for eligibility. A total of 320 studies were included in the final synthesis. A Development, Evaluation and Application Chart (DEAC) of all biomarkers was developed. Most studies focus on identifying new biomarkers and search for relations between these biomarkers and traditional molecular characteristics. Biomarkers are usually investigated in only one study (68.8%). Only 9.8% of all biomarkers was investigated in more than five studies. Circulating tum...

Breast cancer remains a complex and multifaceted disease, necessitating the identification of novel biomarkers for effective monitoring of its evolution. This paper explores the evolving role of hemoglobin variations as a potential indicator in understanding and tracking breast cancer progression. Hemoglobin, primarily recognized for its oxygen transport function, has emerged as a promising biomarker due to its dynamic alterations within the tumor microenvironment. Through an extensive synthesis of current literature, this review elucidates the intricate relationship between hemoglobin fluctuations and breast cancer evolution. It discusses the molecular mechanisms underlying hemoglobin modifications, their correlation with tumor characteristics, and their clinical implications for disease monitoring. Furthermore, it outlines the diagnostic potential of hemoglobin indices in guiding treatment strategies, predicting patient outcomes, and enhancing personalized medicine in breast cancer management. However, challenges persist in standardizing measurement techniques and interpreting hemoglobin variations accurately. This review also identifies these limitations and proposes future research directions to optimize the clinical utility of hemoglobin as a biomarker for monitoring breast cancer evolution. In conclusion, understanding the significance of hemoglobin dynamics offers a promising avenue for refining prognostication, treatment assessment, and improving overall outcomes in breast cancer patients.

Objective: Breast carcinoma is the most common cancer worldwide. The incidence and mortality rate is increasing in developing countries as compare to developed countries. The aim of this study was to assess complete blood count of the breast cancer patients to determine their prognostic values during the different courses of chemotherapy treatment. Methods: In the present study, two hundred breast cancer patients were selected to study prognostic significance of peripheral blood of breast cancer patients. Results: The mean age of breast cancer patients was 47.49±10.43. A decrease in mean value of Hb concentration was observed from12g/dl ±1.45 to 10.9g/dl ±1.54. Platelet count was observed to be increased as the treatment proceeds from first chemotherapy to fifth course of chemotherapy. A decreased pattern of number of total leukocyte and lymphocyte count was noted during chemotherapy treatment. No significant variation was observed for neutrophils, Eosinophil and monocyte count during the different courses of chemotherapy treatment. Conclusion: In conclusion, present results suggest the prognostic significance of the complete blood cell countin the disease monitoring and metastasis. Keywords: Breast cancer, complete blood count, chemotherapy, prognostic significance.

Besides its role as oxygen transporter, recent findings suggest that haemoglobin beta (HBB) may have roles in other contexts. We evaluated the impact of HBB expression in primary human breast cancers, and in breast cancer cell lines overexpressing HBB by in vitro and in vivo studies. Publicly available microarray databases were used to perform multivariate survival analyses. A significantly higher expression of HBB was observed in invasive carcinoma histotypes vs in situ counterparts, along with a positive correlation between HBB and the Ki67 proliferation marker. HBB-overexpressing breast cancer cells migrate and invade more, show HIF-1α upregulation and their conditioned media enhances angiogenesis. Blocking the oxygen-binding site of HBB reverts the increase of migration and HIF-1α upregulation observed in HBB-overexpressing breast cancer cells. Orthotopically implanted MDA-MB-231 overexpressing HBB (MDA-HBB) generated tumours with faster growth rate and increased neoangiogenesis...

The role of blood tumor markers in monitoring response in advanced breast cancer is established in endocrine therapy and standard chemotherapy. This study examines marker levels in patients receiving new chemotherapy regimens. Thirty patients were recruited into two multicenter trials in which docetaxel-based regimens were used in 15 patients. The other 15 received doxorubicin-based regimens. Biochemical response calculated from a score using CA15.3, CEA and ESR was compared with UICC response. Marker changes at 2, 4 and 5 months correlated with UICC response at 3, 41/2 and 6 months, respectively (p < 0.03). Eleven patients achieved both clinical/radiological and biochemical response at the end of treatment; markers had not yet returned to below cutoffs in seven, suggesting a possible advantage to continue chemotherapy. No patient showed a biochemical response whilst judged clinically/radiologically progressive. Nineteen patients had progressed either clinically/radiologically or...

Recently, some studies indicate that paraneoplastic syndrome may be the first sign of lung cancer and may serve in early detection of cancer. Namely, during the last ten years, an increasing importance is given to hematological paraneoplastic syndrome of lung cancer. The aim of this study was to evaluate whether hemoglobin levels have paraneoplastic nature in patients diagnosed with lung cancer prior to any form of therapy, and to examine its relationships with platelet count. The study included 239 patients with lung cancer who were hospitalized at the Clinic for Pulmonary Diseases, Clinical Center of Sarajevo, during the period from January 2005 to December 2008, and a control group of 60 healty persons. The study did not include lung cancer patients with evident hemoptysis and patients who were under chemotherapy and/or were undergoing surgery. The results of our study have shown that the average hemoglobin for each histopathological type of lung cancer was significantly lower th...